What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner (VKTX)
marrio31 Shares of Viking Therapeutics (NASDAQ:VKTX) have surged in the last 12 months, driven by the success of its obesity candidate, the subcutaneously administered VK2735. VK2735’s efficacy, safety and tolerability data to date look very competitive, even when compared to the so-called triple G agonists such as Eli Lilly’s (LLY) retatrutide. And more recently, the…